primary antidote for acetaminophen toxicity Alpha-lipoic acid (ALA): Regenerates antioxidants and supports liver mitochondrial function Milk thistle: Protects hepatocytes and supports liver detox enzymes Sulforaphane: Activates Nrf2, increasing glutathione synthesis and detox capacity Vitamin C + selenium: Replenish antioxidant reserves depleted by acetaminophen use Nutritional & Lifestyle Foundations Support liver function with bitter greens (dandelion, arugula), beets, and lemon water Include sulfur-rich foods (garlic, onions, eggs) to support glutathione production Maintain hydration and avoid alcohol , which compounds liver toxicity Use supportive detox modalities such as infrared sauna when appropriate Functional Medicine Testing and Recovery Strategies Assess ALT, AST, GGT, glutathione status, and oxidative stress markers (e.g., 8-OHdG) Evaluate detox capacity, including relevant genetic SNPs (GST, MTHFR, COMT) Support phase I/II detox pathways with NAC, glycine, and cruciferous extracts Explore drug-free pain and fever strategies such as acupuncture, red-light therapy, PEMF, peptide therapy, magnesium, and hydrogen-rich water NSAIDs: Long-Term Risks, Gut Damage, Cardiovascular Strain, and Impaired Tissue Repair How NSAIDs Suppress Prostaglandins and Impair Healing NSAIDs are among the most commonly used medications for pain and inflammation
Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis
Molteni, Chen
NPW-induced decreases in BPnd in the dorsal striatal ROI were significantly different from changes in BPnd in the ventral striatal ROI ( p = 0.002)
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Interestingly, treated CUS mice did not benefit from reduced appetite or weight loss, the hallmarks of GLP-1 use, but did exhibit improvements in traits of depression
